the aid library

LIST OPTIONS

Filter

13815

Sort by:

Direction:

Download (76)

View PDF (73)

Mpox Multi-country external situation report n. 37

World Health Organisation (WHO) (2024) C_WHO

22 September 2024

Download (102)

View PDF (89)

Cum să faci ceea ce contează în perioade stresante: Un ghid ilustrat

World Health Organization WHO, Regional Office of Europe (2020) C_WHO

Cum să faci ceea ce contează în perioade stresante este un ghid al OMS de gestionare a stresului, pentru a face faţă mai ușor greutăţilor. Acest ghid ilustrat vine în sprijinul implementării recomandărilor OMS pentru gestionarea stresului.

Download (52)

View PDF (119)

WHO consolidated guidelines on tuberculosis Module 1: prevention - tuberculosis preventive treatment, second edition

World Health Organisation (WHO) (2024) C_WHO

About one fourth of the world’s population is estimated to have been infected with the tuberculosis (TB) bacilli, and about 5–10% of those infected develop TB disease in their lifetime. The risk for TB disease after infection depends on several factors, the most important being the person’s im... more

Download (60)

View PDF (58)

Prevalence, severity and risk factors for asthma in school-going adolescents in KwaZulu Natal, South Africa

Mphahlele, R.; Lesosky, M.; Masekela, R. BMJ Open Respiratory Research (2023) CC

Background Asthma remains highly prevalent, with more severe symptoms in low-income to middle-income countries (LMICs) compared with high-income countries. Identifying risk factors for severe asthma symptoms can assist with improving outcomes. We aimed to determine the prevalence, severity and ris... more

Download (68)

View PDF (58)

International study of asthma and allergies in childhood (ISAAC): rationale and methods

Asher, M.I.; Keil, U.; Anderson, H.R. European Respiratory Journal (1995) CC

he aetiology of asthma and allergic disease remains poorly understood, despite considerable research. The International Study of Asthma and Allergies in Childhood (ISAAC), was founded to maximize the value of epidemiological research into asthma and allergic disease, by establishing a standardized m... more

Download (255)

View PDF (308)

Global spending on health: Weathering the storm

World Health Organization WHO (2020) C_WHO

The 2020 Report analyzes global health spending for 190 countries from 2000 to 2018 and provides insights as to the health spending trajectory from the MDG era to the SDG era prior to the crisis of 2020. The report shows that global spending on health continually rose between 2000 and 2018 and reach... more

Download (116)

View PDF (104)

WHO tool for benchmarking ethics oversight of health-related research involving human participants: user guide

World Health Organization WHO (2023) C_WHO

Jointly developed by WHO’s Regulatory System Strengthening, Regulation and Safety Unit and the Health Ethics & Governance Unit, it is intended to assist countries in evaluating their capacity to provide appropriate ethical oversight of health-related research. In addition to assisting in capacity-... more

Download (126)

View PDF (118)

Financing Global Health 2016: Development Assistance, Public and Private Health Spending for the Pursuit of Universal Health Coverage

Institute for Health Metrics and Evaluation (IHME) Institute for Health Metrics and Evaluation (IHME) (2017) C2

Financing Global Health 2016: Development Assistance, Public and Private Health Spending for the Pursuit of Universal Health Coverage presents a complete analysis of the resources available for health in 184 countries, with a particular focus on development assistance for health (DAH). DAH was estim... more

Download (170)

View PDF (165)

AidData's Tracking Underreported Financial Flows (TUFF) Methodology, Version 1.3.

Strange, A.; M. Cheng; B. Russell et al. AidData at William & Mary (2017) CC

This codebook outlines the set of TUFF procedures that have been developed, tested, refined, and implemented by AidData staff and affiliated faculty at the College of William & Mary. We initially employed these methods to achieve a specific objective: documenting the known universe of officially fin... more

Download (111)

View PDF (117)

Regional variation in the allocation of development assistance for health

Hanlon et al. Pubmed (2014) CC

The Global Burden of Disease (GBD) 2010 Study has published disability-adjusted life year (DALY) data at both regional and country levels from 1990 to 2010. Concurrently, the Institute for Health Metrics and Evaluation (IHME) has published estimates of development assistance for health (DAH) at th... more

Download (156)

View PDF (163)

Tool for the accreditation of research ethics committees

Pan American Health Organization PAHO (2023) C_WHO

The ethical governance of research assumes the existence of a national entity (or subnational if applicable, according to the constitution of a country) in charge of supervising the research ethics committees (RECs) that review and monitor research with human beings. This supervision includes the ac... more

Download (79)

View PDF (186)

Official development assistance for health—how neglected are neglected tropical diseases? An analysis of health financing

Liese B; Schubert L. Science Direct (2009) CC

The increasing amounts of official development assistance (ODA) for health have been aimed primarily at fighting HIV/AIDS, malaria and tuberculosis. Neglected tropical diseases (NTD), one of the most serious public health burdens among the most deprived communities, have only recently drawn the atte... more

Download (138)

View PDF (154)

Sudan Humanitarian Update (23 November 2023)

OCHA (2023) CC

Since fighting between the Sudanese Armed Forces (SAF) and the Rapid Support Forces (RSF) erupted in mid-April, an estimated 6.3 million people have fled their homes, taking refuge inside and outside the country, with children representing about half of the people displaced. Sudan is now the country... more

Download (284)

View PDF (380)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (242)

View PDF (222)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 9 October 2023

World Health Organization WHO (2023) CC

The Infection prevention and control in the context of coronavirus disease 2019 (COVID-19): a living guideline consolidates technical guidance developed and published during the COVID-19 pandemic into evidence-informed recommendations for infection prevention and control (IPC). This living guideline... more

Download (160)

View PDF (149)

Guidance for country validation of viral hepatitis elimination and path to elimination

World Health Organization WHO (2023) C_WHO

Building on the 2021 Interim guidance, this second version and update, incorporates the lessons and feedback from the hepatitis pilots that successfully demonstrated the feasibility of measuring hepatitis B and C impact targets to demonstrate elimination, whilst highlighting challenges caused by hig... more

Download (139)

View PDF (143)

Towards UHC: thinking public

World Health Organisation (WHO) (2017) C_WHO

Past quantitative research on health financing has focused mostly on the level and distribution of total expenditure, with little emphasis on the specific role of public funds, despite their known importance for universal health coverage (UHC). Health Accounts data do not disaggregate public expendi... more

Download (116)

View PDF (118)

Tracking development assistance for health to fragile states: 2005-2011

Graves C. et al. Pubmed (2023) CC

Development assistance for health (DAH) has grown substantially, totaling more than $31.3 billion in 2013. However, the degree that countries with high concentrations of armed conflict, ethnic violence, inequality, debt, and corruption have received this health aid and how that assistance might be d... more

Download (166)

View PDF (146)

Public health resource pack for countries experiencing outbreaks of influenza in animals: revised guidance

World Health Organisation (WHO) (2023) C_WHO

This resource pack was developed for the country offices of the World Health Organization and national Public Health institutions, as an overview of the key information needed for advising their Member States in response to questions raised on human health due to influenza outbreaks or detections in... more

Download (140)

View PDF (168)

Medical treatment of cystic echinococcosis: systematic review and meta-analysis

Velasco-Tirado, V.; Alonso-Sardón, M.; Lopez-Bernus, A. et al BMC Infectious Diseases (2018) C2

Cystic echinococcosis (CE) is a well-known neglected parasitic disease. However, evidence supporting the four current treatment modalities is inadequate, and treatment options remain controversial. The aim of this work is to analyse the available data to answer clinical questions regarding medical t... more